The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 30, 2016

Filed:

Jul. 26, 2012
Applicants:

Vincent P. Sandanayaka, Northboro, MA (US);

Sharon Shacham, Newton, MA (US);

Michael Kauffman, Newton, MA (US);

Sharon Shechter, Andover, MA (US);

Dilara Mccauley, Arlington, MA (US);

Yosef Landesman, Brookline, MA (US);

William Senapedis, Millis, MA (US);

Jean-richard Saint-martin, Walpole, MA (US);

Inventors:

Vincent P. Sandanayaka, Northboro, MA (US);

Sharon Shacham, Newton, MA (US);

Michael Kauffman, Newton, MA (US);

Sharon Shechter, Andover, MA (US);

Dilara McCauley, Arlington, MA (US);

Yosef Landesman, Brookline, MA (US);

William Senapedis, Millis, MA (US);

Jean-Richard Saint-Martin, Walpole, MA (US);

Assignee:

Karyopharm Therapeutics Inc., Newton, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 401/08 (2006.01); C07D 401/12 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); C07D 487/10 (2006.01); C07D 401/06 (2006.01);
U.S. Cl.
CPC ...
C07D 403/06 (2013.01); C07D 401/06 (2013.01); C07D 401/08 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 487/10 (2013.01);
Abstract

The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.


Find Patent Forward Citations

Loading…